G1T38
CAS No. 1628256-23-4
G1T38 ( Lerociclib;G1T 38 )
Catalog No. M12425 CAS No. 1628256-23-4
G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 178 | Get Quote |
|
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameG1T38
-
NoteResearch use only, not for human use.
-
Brief DescriptionG1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
-
DescriptionG1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively; shows weak inhibitory effect on CDK9/cyclin T (IC50=28 nM) and CDK5/p35 (IC50=832 nM), >1,000-fold selectivity over CDK1/2/7; decreases RB1 phosphorylation, causes G1 arrest, and inhibits cell proliferation in a variety of CDK4/6-dependent tumorigenic cell lines; demonstrates equivalent or improved tumor efficacy compared to palbociclib in an ER+ breast cancer xenograft model.Breast Cancer,Phase 2 Clinical
-
SynonymsLerociclib;G1T 38
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaCancer
-
IndicationBreast Cancer
Chemical Information
-
CAS Number1628256-23-4
-
Formula Weight474.61
-
Molecular FormulaC26H34N8O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
-
Chemical Name2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bisi JE, et al. Oncotarget. 2017 Jun 27;8(26):42343-42358.
2. Stice JP, et al. Mol Cancer Res. 2017 Jun;15(6):660-669.
2. Stice JP, et al. Mol Cancer Res. 2017 Jun;15(6):660-669.
molnova catalog
related products
-
CYC065
CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
-
THZ-1 hydrochloride
THZ-1 hydrochloride is a potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM.
-
BAY 1251152
BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.